MIAMI, Oct. 1 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK)
has announced the appointment of Pascal J. Goldschmidt, M.D. to its Board
of Directors. Dr. Goldschmidt is the Senior Vice President for Medical
Affairs and Dean of the University of Miami Leonard M. Miller School of
Medicine. Dr. Goldschmidt formerly served as Chairman of the Department of
Medicine at Duke University Medical Center.

"We are delighted to welcome an exceptional healthcare leader like
Pascal Goldschmidt to our Board," said Phillip Frost, M.D., Chairman and
CEO of OPKO Health. "We expect the insight and experience gained from his
distinguished record of achievement at several of our most respected
academic medical institutions will be very valuable to our efforts to build
a successful company dedicated to providing novel diagnostic and
therapeutic products to physicians and their patients."

Before assuming his current position, Dr. Goldschmidt was Chief of
Cardiology and then promoted to Chairman of the Department of Medicine at
Duke University Medical Center. Earlier in his career, Dr. Goldschmidt was
Director of Cardiology at The Ohio State University College of Medicine and
Public Health, where he built the Heart and Lung Research Institute and a
cardiology specialty hospital.

Dr. Goldschmidt serves on the Board of Directors of Pediatrix Medical
Group, Inc. He received an M.D. degree from Universite Libre de Bruxelles
and completed residency and fellowship training in Belgium at Erasme
Academic Hospital and in the United States at The Johns Hopkins University.

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead
investigational drug, the pioneering gene silencing agent bevasiranib, has
entered a pivotal Phase III trial after successfully completing Phase II
trials for wet age-related macular degeneration and diabetic macular edema.
OPKO is developing a preclinical pipeline of novel agents for ophthalmic
diseases and markets diagnostic systems that complement its therapeutic
products. For more information visit the company's website at
http://www.opko.com.

This press release contains "forward-looking statements," as that term
is defined under the Private Securities Litigation Reform Act of 1995
(PSLRA), which statements may be identified by words such as "expects,"
"plans," "projects," "will," "may," "anticipates," "believes," "should,"
"intends," "estimates," and other words of similar meaning, including
statements regarding our product development efforts, our ability to
develop a preclinical pipeline of novel agents for ophthalmic diseases, our
ability to market diagnostic systems that complement our therapeutic
products, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business, technologies
and products, financial condition, strategies or prospects. Many factors
could cause our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements. These
factors include those described in our filings with the Securities and
Exchange Commission, as well as risks inherent in funding, developing and
obtaining regulatory approvals of new, commercially-viable and competitive
products and treatments, including the risks that enrollment of patients
for the Phase 3 clinical trial for bevasiranib, may not be successful, that
the Phase 3 clinical trial itself may not be completed on a timely basis or
at all, that any of our compounds under development, including bevasiranib,
may fail, may not achieve the expected results or effectiveness and may not
generate data that would support the approval or marketing of products for
the indications being studied or for other indications. In addition,
forward-looking statements may also be adversely affected by general market
factors, competitive product development, product availability, federal and
state regulations and legislation, the regulatory process for new products
and indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward- looking statements contained
in this press release speak only as of the date the statements were made,
and we do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.

(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...

(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...

(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...

(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...

(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...

(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...

(Date:9/27/2017)... 27, 2017 Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...

(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...